TP53-Mutated Myelodysplastic Syndrome and Acute Myeloid Leukemia: Biology, Current Therapy, and Future Directions

TP53-mutated myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML) form a distinct group of myeloid disorders with dismal outcomes. TP53-mutated MDS and AML have lower response rates to either induction chemotherapy, hypomethylating agent–based regimens, or venetoclax-based therapies compa...

Descripción completa

Detalles Bibliográficos
Autores principales: Daver, Naval G., Maiti, Abhishek, Kadia, Tapan M., Vyas, Paresh, Majeti, Ravindra, Wei, Andrew H., Garcia-Manero, Guillermo, Craddock, Charles, Sallman, David A., Kantarjian, Hagop M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Association for Cancer Research 2022
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9627130/
https://www.ncbi.nlm.nih.gov/pubmed/36218325
http://dx.doi.org/10.1158/2159-8290.CD-22-0332

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9627130/
https://www.ncbi.nlm.nih.gov/pubmed/36218325
http://dx.doi.org/10.1158/2159-8290.CD-22-0332

Ejemplares similares